Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R43/R44 - Clinical Trials Optional) | RFA DA 26 018

Opportunity Information: Apply for RFA DA 26 018

The funding opportunity "Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R43/R44 - Clinical Trials Optional)" (RFA-DA-26-018) is a National Institutes of Health (NIH) small business grant program focused on improving how emerging drugs and drug adulterants are detected in real-world settings. The core problem it targets is that the illicit drug supply keeps changing, with substances such as xylazine and nitazenes already appearing in circulation and additional, unknown threats likely to follow. Public health and harm reduction efforts depend on being able to identify what is actually present in samples taken from the field, but many new or fast-evolving compounds do not have simple, commercially available rapid tests.

The opportunity highlights the current reliance on testing strips for quick drug checking. Strips are popular because they are fast, sensitive, low-cost, and generally accurate, but they only work for the specific drugs they are designed to detect. When a new threat appears and no strip exists for it, programs and laboratories need other approaches that do not depend on having a dedicated single-analyte strip for every new compound. That is the main motivation for this solicitation: advancing sensitive, broadly applicable (sample-agnostic) analytical methods and the instrumentation that enables them. In practical terms, the government is looking to stimulate development of tools and workflows that can detect a wide range of known and emerging substances in complex, real-world samples, rather than being limited to a narrow set of targets.

This solicitation uses the NIH small business mechanisms R43/R44, which correspond to the Small Business Innovation Research (SBIR) program and are designed to support product-oriented R and D. The intent of these mechanisms is typically to move promising technologies from feasibility and prototyping toward development and, ultimately, real-world deployment. The listing notes "Clinical Trials Optional," meaning applicants may propose work that includes a clinical trial if it is appropriate to the technology and research plan, but a clinical trial is not required. The activity area is aligned with health and education, and the CFDA/Assistance Listing number provided is 93.279, which is associated with drug abuse and addiction-related research portfolios.

Eligibility is centered on small businesses, consistent with SBIR rules, and the notice indicates there may be additional eligible applicant categories, with the instruction to consult the full Notice of Funding Opportunity (NOFO) for the complete eligibility details. The sponsoring agency is NIH, and given the topic area and the RFA identifier prefix "DA," the scientific mission alignment is in the substance use and drug detection space. The opportunity is categorized as a discretionary grant. The posting indicates an original closing date of 2025-02-19 and a creation date of 2024-11-04. The provided source text does not list an award ceiling or expected number of awards, suggesting those specifics either were not included in the excerpt or are detailed in the full NOFO.

Overall, this grant opportunity is aimed at accelerating new analytical instrumentation and alternative detection methods that can keep pace with a rapidly shifting drug landscape. The emphasis is on solutions capable of analyzing real-world samples with high sensitivity and broad applicability, addressing the gap left when rapid test strips are unavailable for newly emerging substances like xylazine, nitazenes, and whatever compounds appear next.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R43/R44 - Clinical Trials Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279.
• This funding opportunity was created on 2024-11-04.
• Applicants must submit their applications by 2025-02-19. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: Small businesses.

Apply for RFA DA 26 018

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: